Ipamorelin: the complete research guide.

Ipamorelin is a five-amino-acid peptide that tells the pituitary to release growth hormone, and it's the cleanest GHRP in the class. It raises GH without the cortisol, prolactin and appetite effects of older GHRPs. Its evidence stops short of the clinic: the one Phase III trial it ran missed its endpoint.

The ipamorelin story is the GH-axis-peptide story in miniature. It is a real molecule with a real mechanism. A serious pharma company developed it. It worked exactly as designed in early pharmacology studies.

Then it failed its one major clinical test. That test was for an unrelated indication. It then drifted into research-supply channels. Today it is one of the two most-discussed GH-axis peptides in grey-market protocols.

This guide covers what ipamorelin is. It covers why its cleanness matters for research design. Then where it sits in the GHRP family. Then what the published literature does and does not support. And last, how its regulatory status shapes what you can buy.

What is ipamorelin?

Ipamorelin is a synthetic pentapeptide. Novo Nordisk developed it in the late 1990s. The sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH₂. That is 5 amino acids total, 2 of them non-natural. Those non-natural residues give it stability in blood. They also give it cleaner cell-surface targeting than natural ghrelin or older GHRPs.

The molecular target is GHS-R1a, the cell-surface receptor your own ghrelin binds. Ghrelin is the “hunger hormone,” made mostly in the stomach.

GHS-R1a sits on GH-producing somatotrophs in the anterior pituitary. It also sits on arcuate-nucleus neurons in the hypothalamus, and on various peripheral tissues. Activating it drives GH release, appetite and energy-balance signaling.

Ipamorelin differs from the older agents in what it doesn't activate. The older agents are GHRP-2, GHRP-6 and hexarelin. Those push cortisol, prolactin and ACTH up alongside GH. GHRP-6 does it most.

Those collateral effects come from incomplete cell-surface selectivity. Ipamorelin's clinical pharmacology showed minimal movement on those side axes at GH-stimulating doses. That's the attribute we keep coming back to.

A 2026 review by Rahman and colleagues in the Journal of the AAOS Global Research and Reviews groups ipamorelin with CJC-1295, tesamorelin, sermorelin and AOD-9604 as growth hormone secretagogues.

Strictly, ipamorelin's target differs from the GHRH target the rest of that group binds. We list it that way because that's how clinicians categorize it.

Why ipamorelin's selectivity matters in research.

We think ipamorelin became a standard pharmacological tool because of the cleanness of the readout, not the marketing. Characterizing GH-axis dynamics requires a stimulus that hits one target and one downstream pathway. Older GHRPs that also elevate cortisol introduce confounders. Cortisol blocks GH's anabolic effects. Prolactin has separate metabolic actions. ACTH alters glucocorticoid signaling.

Ipamorelin isolates the GH-axis effect from that noise, which makes a cleaner question tractable in rodents. Are the effects driven by GH release specifically, or by the broader stress-axis activation GHRP-6 produces?

A 2020 rat study by Mohammadi and colleagues found ipamorelin reduced colonic and somatic pain in non-inflammatory models. A ghrelin-pathway blocker abolished the effect, which is the specificity that separates it from older GHRPs.

That selectivity also explains why ipamorelin shows up in the CJC-1295 combination studies instead of GHRP-2 or GHRP-6.

Pairing a GHRH analog with a ghrelin-pathway agent only works if the ghrelin side doesn't spike cortisol at the same time. Cortisol would blunt the downstream anabolic signal you're trying to produce.

Preclinical findings: what the rodent work actually shows.

Ipamorelin's preclinical literature in the 2020s falls into three buckets: cachexia, meaning wasting, plus pain and reproductive-axis effects. We found very little new work on the muscle-mass or body-composition endpoints that drive grey-market use.

Cachexia. A 2024 ferret study from Lu and colleagues found ipamorelin at 1–3 mg/kg intraperitoneally blocked cisplatin-induced weight loss in the delayed phase of chemo-induced nausea.

Ipamorelin did not stop the vomiting itself. The weight-protective effect runs on a different mechanism, probably appetite stimulation and metabolic preservation through ghrelin signaling.

Visceral and somatic pain. The 2020 Mohammadi et al. rat study showed ipamorelin reduced colonic and somatic pain in non-inflammatory models. Effects were blocked by a ghrelin-pathway blocker. That's mechanistically interesting because it identifies a peripheral ghrelin mechanism for pain relief. It's distinct from the central GH-release pathway. It opens up applications outside the classical “GH stimulation” story.

Reproductive axis. A 2024 study in tilapia, a fish used in reproductive endocrinology, found ipamorelin acetate raised spermatogenesis, luteinizing hormone and 11-ketotestosterone.

That's several inferential steps from human reproductive biology. It does suggest the ghrelin system has reproductive effects worth chasing in mammalian models.

What the preclinical literature doesn't robustly demonstrate is muscle-mass accrual, fat reduction or senescence effects in healthy animals.

A 2026 review in the American Journal of Sports Medicine notes ipamorelin with CJC-1295 significantly improved muscle tetanic tension in mice with glucocorticoid-induced muscle loss. That's a cachexia model, not healthy animals in training.

The Phase III ileus trial: the one major human readout.

This is the most important real-world data point in ipamorelin's clinical history. It's also the one most often skipped in grey-market discussions. Novo Nordisk pushed ipamorelin into Phase III trials for postoperative ileus, the bowel-stopping condition that often follows abdominal surgery. The theory was that ghrelin-pathway activation would restart gastrointestinal motility.

The trial failed. Ipamorelin missed its primary endpoint, clinical development stopped, and the molecule was shelved as a therapeutic.

We'd call that the single most informative real-world data point on file. 1 Phase III trial, endpoint missed, program shut. Tested rigorously against a controlled endpoint, the effect wasn't big enough to support an approval.

That doesn't mean ipamorelin does nothing in humans. It plausibly does release GH, and we'd call the cell-surface pharmacology well established.

It does mean the threshold for clinical efficacy on a real endpoint, once somebody measured it, wasn't cleared. That's a different kind of evidence from “the mechanism is plausible.”

Where the human efficacy data stops.

Outside the failed ileus trial, the human evidence base is essentially empty. We found no published randomized controlled trial testing ipamorelin for any of the indications grey-market discussions cite most.

• Muscle-mass or lean-body-mass endpoints in healthy adults or athletes
• Adipose-tissue or body-composition endpoints in any population
• Senescence or longevity endpoints
• Tissue-repair endpoints after training or injury
• Sleep architecture, sexual function, or cognition

A 2026 review by Mendias and Awan in Sports Medicine concludes the same thing. Ipamorelin turns up constantly in grey-market protocols, and robust human evidence for performance, body composition or recovery is absent.

The same review files ipamorelin among unapproved peptides where human safety data is scarce and serious harm can't be ruled out.

Here's the honest reading. Ipamorelin's case in 2026 rests on 3 pillars, and none of them is an outcome.

First, clinical-pharmacology data showing it causes GH release. That's true, and it's biomarker-level. Second, cell-surface-specific preclinical experiments, informative for mechanism rather than for clinical effect.

Third, inference from the broader GH-axis literature. That literature is mostly tesamorelin in HIV lipodystrophy, a very different population from anyone buying this.

The CJC-1295 + ipamorelin pairing.

In 2026, ipamorelin is almost always reported alongside CJC-1295 no DAC, in the literature and in grey-market discussion alike.

The pairing has a coherent mechanistic basis. CJC-1295 activates the GHRH pathway, ipamorelin activates the ghrelin pathway, and together they produce a larger GH pulse than either alone. The two run complementary signaling cascades inside the GH-producing cells.

What matters about the pairing is that it's a mechanism-based combination, not an outcomes-based one.

The administration patterns in grey-market literature come from clinical-pharmacology studies that established the synergistic GH release. They don't come from controlled human trials measuring tissue benefit. The assumption that more GH means more benefit has never been formally validated.

This is relevant because GH-axis biology has well-documented feedback dynamics. Sustained or repeated synergistic pulses can drive tolerance buildup, liver resistance to GH signaling, and adaptive changes that dampen the response. Whether the combination's acute effect translates to durable benefit, or whether a transient biomarker elevation simply fades, is untested in controlled human studies.

Risks, side effects, and the unknowns.

The adverse-event profile documented for ipamorelin matches the broader GHRP class. The one caveat is that cleaner cell-surface targeting should reduce the cortisol and prolactin elevations older GHRPs produce. Here are the risks the published literature names.

• GH-axis side effects when GH is elevated supraphysiologically: edema (fluid retention), joint stiffness, paresthesias (tingling), insulin resistance, theoretical IGF-1-mediated oncogenic concerns.
• Tolerance buildup. Continuous ghrelin-pathway activation may cause cell-surface downregulation. Grey-market literature describes pulsatile administration patterns on this basis, though no controlled human evidence supports a specific schedule.
• Cross-reactivity caveat. A 2021 method paper noted some compounds (cannabidiol and carboxy-THC) act as allosteric ghrelin-pathway ligands and may interact with ipamorelin effects in unexpected ways (Danila et al., 2021).
• Long-term safety: no long-term human safety data exist for ipamorelin in healthy, non-clinical populations. The Phase III postoperative ileus trial population represents the largest controlled exposure on record, and that was a short-duration acute hospital indication.
• Pharmacy compounding restrictions. FDA placed ipamorelin among substances ineligible for 503A pharmacy compounding in recent years, restricting legal clinical access.

Regulatory status.

Ipamorelin isn't approved by FDA, EMA, or any major regulatory body for any indication. Clinical development was discontinued after the Phase III ileus failure. It's on the WADA Prohibited List under category S2. Reliably detectable in athlete samples by validated LC-MS/MS methods. Major sports leagues prohibit its use.

The FDA's decision to list ipamorelin among substances ineligible for 503A compounding is what pushed it out of clinical channels and into research-supply-only distribution.

Like CJC-1295, ipamorelin now works mostly as a research tool in in-vitro and animal studies of GH-axis pharmacology. Grey-market human use runs in parallel, outside the regulated supply chain, which is where you'll find it.